MedTrace Logo

Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac

NCT07733219 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-07-29

No results posted yet for this study

Summary

Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled oligometastatic disease. The study investigates the potential of this innovative technology, which enables real-time treatment adaptation, with the goal of optimizing the benefit-risk ratio in a population at high risk of radiotherapy-related toxicity

Conditions

  • Ultracentral Pulmonary Tumors
  • Lung Cancer (T1 N0 M0 and T2 N0 M0)
  • Mediastinal Lymph Node Recurrence From All Types of Primary Cancer
  • Pulmonary Node Recurrence From All Types of Primary Cancer

Interventions

RADIATION

MRI-LINAC radiotherapy

Stereotactic body radiotherapy (SBRT) is delivered using an MRI-guided linear accelerator (MR-LINAC), at a total dose of 60 Gy in 8 fractions (7.5 Gy per fraction) over 17 days. Treatment is performed using MR-guided adaptive radiotherapy with real-time imaging and respiratory motion management (gating).

Sponsors & Collaborators

  • Aquilab SAS

    collaborator UNKNOWN

  • Centre François Baclesse (CTD-CNO)

    collaborator UNKNOWN

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Florence LE TINIER, MD · Centre Oscar Lambret, Lille

  • David PASQUIER, MD, PhD · Centre Oscar Lambret, Lille

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2031-11-01
Completion
2031-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07733219 on ClinicalTrials.gov